AU2013248138B2 - Methods for determining a breast cancer-associated disease state and arrays for use in the methods - Google Patents

Methods for determining a breast cancer-associated disease state and arrays for use in the methods Download PDF

Info

Publication number
AU2013248138B2
AU2013248138B2 AU2013248138A AU2013248138A AU2013248138B2 AU 2013248138 B2 AU2013248138 B2 AU 2013248138B2 AU 2013248138 A AU2013248138 A AU 2013248138A AU 2013248138 A AU2013248138 A AU 2013248138A AU 2013248138 B2 AU2013248138 B2 AU 2013248138B2
Authority
AU
Australia
Prior art keywords
breast cancer
control sample
cancer cells
amount
biomarker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013248138A
Other languages
English (en)
Other versions
AU2013248138A1 (en
Inventor
Carl Arne Krister Borrebaeck
Christer Lars Bertil Wingren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunovia AB
Original Assignee
Immunovia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunovia AB filed Critical Immunovia AB
Publication of AU2013248138A1 publication Critical patent/AU2013248138A1/en
Application granted granted Critical
Publication of AU2013248138B2 publication Critical patent/AU2013248138B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2446/00—Magnetic particle immunoreagent carriers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
AU2013248138A 2012-04-10 2013-04-10 Methods for determining a breast cancer-associated disease state and arrays for use in the methods Ceased AU2013248138B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1206323.6A GB201206323D0 (en) 2012-04-10 2012-04-10 Methods and arrays for use in the same
GB1206323.6 2012-04-10
PCT/IB2013/052858 WO2013153524A1 (en) 2012-04-10 2013-04-10 Methods for determining a breast cancer-associated disease state and arrays for use in the methods

Publications (2)

Publication Number Publication Date
AU2013248138A1 AU2013248138A1 (en) 2014-11-27
AU2013248138B2 true AU2013248138B2 (en) 2019-01-17

Family

ID=46177101

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013248138A Ceased AU2013248138B2 (en) 2012-04-10 2013-04-10 Methods for determining a breast cancer-associated disease state and arrays for use in the methods

Country Status (10)

Country Link
US (2) US20150057177A1 (enExample)
EP (1) EP2836838A4 (enExample)
JP (1) JP6470681B2 (enExample)
KR (1) KR20140143457A (enExample)
CN (2) CN107782901A (enExample)
AU (1) AU2013248138B2 (enExample)
CA (1) CA2869696A1 (enExample)
GB (1) GB201206323D0 (enExample)
MX (1) MX2014012192A (enExample)
WO (1) WO2013153524A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201410226D0 (en) * 2014-06-09 2014-07-23 Immunovia Ab Methods and arrays for use in the same
CN106596494B (zh) * 2016-12-29 2019-05-10 青岛科技大学 一种基于荧光传感阵列的快速筛查早中晚期乳腺癌技术
GB201701572D0 (en) * 2017-01-31 2017-03-15 Immunovia Ab Methods, arrays and uses thereof
CN111458512A (zh) * 2019-01-21 2020-07-28 中国科学院分子细胞科学卓越创新中心 一种动脉粥样硬化生物标志物及其用途
JP7352937B2 (ja) * 2019-07-19 2023-09-29 公立大学法人福島県立医科大学 乳癌のサブタイプを鑑別又は分類するための鑑別マーカー遺伝子セット、方法およびキット
CA3206126A1 (en) * 2021-01-15 2022-07-21 Universite De Fribourg Biomarkers for breast cancer detection

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005005601A2 (en) * 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990077146A (ko) * 1996-01-11 1999-10-25 길리스 스티브 유방암의 치료 및 진단용 조성물 및 방법
US20030138793A1 (en) * 2001-06-10 2003-07-24 Irm Llc, A Delaware Limited Liability Company Molecular signatures of commonly fatal carcinomas
WO2004106495A2 (en) * 2003-05-29 2004-12-09 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
JP2005270093A (ja) * 2004-02-24 2005-10-06 Nippon Medical School 乳癌の術後予後予測に関与する遺伝子
US20080026950A1 (en) * 2004-02-24 2008-01-31 Mitsubishi Rayon Co., Ltd. Gene Relating to Estimation of Postoperative Prognosis for Breast Cancer
WO2006105642A1 (en) * 2005-04-05 2006-10-12 British Columbia Cancer Agency Biomarkers for the detection of lung cancer and uses thereof
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
SG142186A1 (en) * 2006-10-20 2008-05-28 Agency Science Tech & Res Breast tumour grading
JP5196465B2 (ja) * 2007-04-24 2013-05-15 公益財団法人東京都農林水産振興財団 Ｍｍｐ遺伝子発現促進剤、および、コラーゲン分解促進剤
NZ562237A (en) * 2007-10-05 2011-02-25 Pacific Edge Biotechnology Ltd Proliferation signature and prognosis for gastrointestinal cancer
GB0723179D0 (en) * 2007-11-27 2008-01-02 Immunovia Ab Diagnostic methods and arrays for use in the same
US8519116B2 (en) * 2008-04-29 2013-08-27 Siemens Healthcare Diagnostics Inc. Method for predicting a clinical response of a patient suffering from or at risk of developing cancer towards a given mode of treatment
JP2010151800A (ja) * 2008-11-06 2010-07-08 Kumamoto Univ 生活習慣病及び／又は癌の診断剤
WO2010076322A1 (en) * 2008-12-30 2010-07-08 Siemens Healthcare Diagnostics Inc. Prediction of response to taxane/anthracycline-containing chemotherapy in breast cancer
WO2010088386A1 (en) * 2009-01-28 2010-08-05 University Of Notre Dame Du Lac Accelerated progression relapse test
WO2011063274A2 (en) * 2009-11-23 2011-05-26 Genomic Health, Inc. Methods to predict clinical outcome of cancer
WO2011065533A1 (ja) * 2009-11-30 2011-06-03 国立大学法人大阪大学 乳癌術前化学療法に対する感受性の判定方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005005601A2 (en) * 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ellsworth et al. (Clin Exp Metastasis 2009 VOl. 26 p. 205) *

Also Published As

Publication number Publication date
AU2013248138A1 (en) 2014-11-27
WO2013153524A1 (en) 2013-10-17
JP6470681B2 (ja) 2019-02-13
EP2836838A1 (en) 2015-02-18
CN104508486B (zh) 2019-06-04
US20180284120A1 (en) 2018-10-04
CN107782901A (zh) 2018-03-09
WO2013153524A9 (en) 2014-03-13
CN104508486A (zh) 2015-04-08
GB201206323D0 (en) 2012-05-23
EP2836838A4 (en) 2016-03-30
CA2869696A1 (en) 2013-10-17
US20150057177A1 (en) 2015-02-26
KR20140143457A (ko) 2014-12-16
JP2015519043A (ja) 2015-07-09
MX2014012192A (es) 2015-05-11

Similar Documents

Publication Publication Date Title
US20180284120A1 (en) Methods for determining a breast cancer-associated disease state and arrays for use in the methods
Olsson et al. Grading breast cancer tissues using molecular portraits
Chen et al. Comparison of membrane fraction proteomic profiles of normal and cancerous human colorectal tissues with gel‐assisted digestion and iTRAQ labeling mass spectrometry
CN105283763B (zh) 用于前列腺癌的生物标志物检测中的方法和阵列
CA2950047A1 (en) Methods and arrays for use in the same
EP3545108A1 (en) Biomarkers for the prognosis and diagnosis of cancer
WO2022207671A1 (en) Proteogenomic analysis of non-small cell lung cancer
JP2019032334A (ja) 乳癌関連の疾患状態を決定する方法およびこの方法における使用のためのアレイ
WO2016178236A1 (en) Methods and kits for breast cancer prognosis
Class et al. Patent application title: METHODS FOR DETERMINING A BREAST CANCER-ASSOCIATED DISEASE STATE AND ARRAYS FOR USE IN THE METHODS Inventors: Carl Arne Krister Borrebaeck (Lund, SE) Carl Arne Krister Borrebaeck (Lund, SE) Christer Lars Bertil Wingren (Sandby, SE)
Kageyama et al. Proteome research in urothelial carcinoma
CA3214821A1 (en) Protein markers for estrogen receptor (er)-positive-like and estrogen receptor (er)-negative-like breast cancer
GB2630774A (en) Lung cancer biomarkers
Kulasingam et al. Proteomic and genomic technologies for biomarker discovery
Jain Oncoproteomics
Boussioutas et al. Genomic and Proteomic Advances in Gastric Cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired